Rubius Therapeutics, Inc.
RUBYDelisted Mar 28, 2023- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001709401
Rubius Therapeutics, Inc. was delisted on Mar 28, 2023; its insiders filed their last Form 4 on Feb 27, 2023; 42 institutions reported holding it in 13F filings for Q4 2022, worth $11.2M in total; no superinvestor held it.
13F holders, Q3 2021
Institutional positions in Rubius Therapeutics, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 105
- −3 vs. Q2 2021
- Shares held
- 86.4M
- +818.7K (+1.0%) vs. Q2 2021
- Total value
- $1.55B
- −$543.7M (−26.0%) vs. Q2 2021
- New holders
- 12
- 36 more added
- Sold out
- 15
- 33 more reduced
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RUBY on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 7 | $61.3K |
| Q4 2022 | 42 | $11.2M |
| Q3 2022 | 62 | $29.7M |
| Q2 2022 | 73 | $66.6M |
| Q1 2022 | 117 | $493.9M |
| Q4 2021 | 108 | $863.6M |
| Q3 2021 | 105 | $1.55B |
| Q2 2021 | 108 | $2.09B |
| Q1 2021 | 105 | $2.23B |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Rubius Therapeutics, Inc.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock Inc. | 3,484,480 | $62.3M | 0.00% | +48,645+1.4% | Added |
| Artal Group S.A. | 4,155,625 | $74.3M | 1.83% | −478,166−10.3% | Reduced |
| Baillie Gifford & Co | 4,693,832 | $83.9M | 0.04% | −1,1900.0% | Reduced |
| FMR LLC | 13,527,493 | $241.9M | 0.02% | 00.0% | Unchanged |
| Flagship Pioneering Inc. | 38,506,526 | $688.5M | 7.21% | 00.0% | Unchanged |
| EAM Investors, LLC | 0 | $0 | 0.00% | −118,095−100.0% | Sold out |
| Voloridge Investment Management, LLC | 0 | $0 | 0.00% | −90,576−100.0% | Sold out |
| EAM Global Investors LLC | 0 | $0 | 0.00% | −75,103−100.0% | Sold out |
| Pathway Capital Management, LP | 0 | $0 | 0.00% | −73,667−100.0% | Sold out |
| SEI Investments Co | 0 | $0 | 0.00% | −35,732−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −17,500−100.0% | Sold out |
| Susquehanna Fundamental Investments, LLC | 0 | $0 | 0.00% | −14,550−100.0% | Sold out |
| Occudo Quantitative Strategies LP | 0 | $0 | 0.00% | −10,542−100.0% | Sold out |
| Twinbeech Capital LP | 0 | $0 | 0.00% | −10,307−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −9,100−100.0% | Sold out |
| Engineers Gate Manager LP | 0 | $0 | 0.00% | −9,011−100.0% | Sold out |
| Amalgamated Bank | 0 | $0 | 0.00% | −8,514−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −3,087−100.0% | Sold out |
| CNB Bank | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Captrust Financial Advisors | 0 | $0 | 0.00% | −10−100.0% | Sold out |